Essential for hypertension management.

© 2017 AtCor Medical Pty Ltd.

Most Recent Tweet

       

  • AtCor signs local health system agreement

    AtCor has entered into a three year network agreement with Emory University and Emory Healthcare of Atlanta, GA.

  • Study finds central aortic waveform improves and enables individualisation of heart failure treatment

    A recent study “Aortic waveform analysis individualizes treatment in heart failure” found that analysis of the central aortic waveform, as measured by SphygmoCor, could predict which heart fialure patients would respond to vasoactive drug therapy.

  • Tax Refund

    Refund received from the Australian Tax Office for $472,133.

  • Central Blood Pressure Associated with Cognitive Decline

    A new study found a significant relationship was observed between central blood pressures, specifically augmentation index (AI) and pulse pressure amplification (PPA), and mild cognitive decline.

  • Positive Novartis drug trial using SphygmoCor XCEL

    PARAMETER study results published in the influential journal Hypertension showed the new drug compound was more effective at reducing central aortic systolic pressure.

  • AtCor secures $0.8 million new pharmaceutical trial contracts

    Three new contracts to supply SphygmoCor systems and clinical trial support services in last 30 days.

  • AtCor signs new Network Health Systems Agreement

    A 24 month agreement has been signed with Nephrology Associates of Northern Illinois and Indiana (NANI) to provide SphygmoCor systems to NANI practices throughout the region

  • AtCor signs local health system agreement

    AtCor has entered into a three year network agreement with Emory University and Emory Healthcare of Atlanta, GA.

  • Study finds central aortic waveform improves and enables individualisation of heart failure treatment

    A recent study “Aortic waveform analysis individualizes treatment in heart failure” found that analysis of the central aortic waveform, as measured by SphygmoCor, could predict which heart fialure patients would respond to vasoactive drug therapy.

  • Tax Refund

    Refund received from the Australian Tax Office for $472,133.

  • Central Blood Pressure Associated with Cognitive Decline

    A new study found a significant relationship was observed between central blood pressures, specifically augmentation index (AI) and pulse pressure amplification (PPA), and mild cognitive decline.

  • Positive Novartis drug trial using SphygmoCor XCEL

    PARAMETER study results published in the influential journal Hypertension showed the new drug compound was more effective at reducing central aortic systolic pressure.

  • Viking Yacht Company adds SphygmoCor for Employee Wellness

    Viking Yachts, a leader in semi-custom fiberglass yacht production, has incorporated SphygmoCor into its employee wellness program

  • Share Purchase Plan Offer

    SPP opens September 5 and closes Monday, September 18, 2017

  • Full Year Statutory Accounts

    FY2017 accounts and Appendix 4E

  • Share Purchase Plan

    AtCor is offering a Share Purchase Plan to raise up to $500,000

  • Appendix 3B

    Issue of new shares

  • Share Placement

    Placement to sophisticated and institutional shareholders, raising $825,000 before costs.

  • AtCor Restructures Operations

    Progress update on the strategic review and announces restructuring to reduce costs and secure new sales

  • AtCor Signs New Agreement

    A two year agreement with New York University to provide SphygmoCor systems to NYU owned and affiliated locations and practices

  • AtCor secures $0.8 million new pharmaceutical trial contracts

    Three new contracts to supply SphygmoCor systems and clinical trial support services in last 30 days.

  • AtCor signs new Network Health Systems Agreement

    A 24 month agreement has been signed with Nephrology Associates of Northern Illinois and Indiana (NANI) to provide SphygmoCor systems to NANI practices throughout the region

  • AtCor signs local health system agreement

    AtCor has entered into a three year network agreement with Emory University and Emory Healthcare of Atlanta, GA.

  • Study finds central aortic waveform improves and enables individualisation of heart failure treatment

    A recent study “Aortic waveform analysis individualizes treatment in heart failure” found that analysis of the central aortic waveform, as measured by SphygmoCor, could predict which heart fialure patients would respond to vasoactive drug therapy.

  • Tax Refund

    Refund received from the Australian Tax Office for $472,133.

  • Central Blood Pressure Associated with Cognitive Decline

    A new study found a significant relationship was observed between central blood pressures, specifically augmentation index (AI) and pulse pressure amplification (PPA), and mild cognitive decline.

  • Positive Novartis drug trial using SphygmoCor XCEL

    PARAMETER study results published in the influential journal Hypertension showed the new drug compound was more effective at reducing central aortic systolic pressure.